Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain
This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein.
1. A method for increasing bone mass, bone density and/or bone strength, comprising: administering to a mammalian animal with a disease selected from the group consisting of osteoporosis, osteoarthritis, articular rheumatism, hypercalcemia, Paget's disease of bone, osteopetrosis, Camurati-engelmann's disease, arthropathy, primary hyperthyreosis, osteopenia, osteohalisteresis, rachitis, traumatic bone fracture, and fatigue bone fracture, an effective amount of a pharmaceutical composition which comprises, as an active ingredient, a protein comprising an extracellular cysteine-rich domain comprising the amino acid sequence of SEQ ID NO:21 or 26, to increase bone mass, bone density and/or bone strength.
2. The method according to claim 1 , wherein the mammalian animal is a human.
3. The method according to claim 1 , wherein the extracellular cysteine-rich domain comprises an amino acid sequence spanning from the 1st cysteine residue on the N-terminal side to the 10th cysteine residue in the amino acid sequence of an extracellular region of a human Frizzled 2 receptor.
4. The method according to claim 1 , wherein the protein comprises the amino acid sequence of SEQ ID NO: 19 or 25.
5. The method according to claim 1 , wherein the protein is a recombinant protein.
6. The method according to claim 1 , wherein the protein is a fusion protein of the extracellular cysteine-rich domain and a mammalian immunoglobulin Fc protein or a mutant thereof prepared so that antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) activities are lowered.
7. The method according to claim 6 , wherein the Fc protein or the mutant thereof comprises the amino acid sequence of SEQ ID NO: 4.
8. The method according to claim 6 , wherein the Fc protein or the mutant thereof comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 3.
9. The method according to claim 1 , wherein the protein is chemically modified.
10. The method according to claim 9 , wherein the chemical modification is a binding of one or more polyethylene glycol molecules.
11. The method according to claim 9 , wherein the chemical modification is a binding of one or more sugar chains.
12. The method according to claim 1 , wherein the composition is simultaneously or continuously administered in combination with another therapeutic agent for increasing bone mass, bone density and/or bone strength.